Sulfur Containing Patents (Class 514/665)
  • Patent number: 10548870
    Abstract: The present invention is directed to a method for treating multiple sclerosis by administering dapansutrile to a subject in need thereof. A preferred route of administration is oral administration.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: February 4, 2020
    Assignee: OLATEC THERAPEUTICS LLC
    Inventor: Charles A. Dinarello
  • Patent number: 10307386
    Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: June 4, 2019
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 10022345
    Abstract: The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: July 17, 2018
    Assignee: SBI PHARMACEUTICALS CO., LTD.
    Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata
  • Patent number: 9925154
    Abstract: Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 27, 2018
    Assignee: Seattle Children's Hospital
    Inventors: Allison A. Eddy, Daryl M. Okamura
  • Patent number: 9919941
    Abstract: A method for treating in an industrial water treatment system for at least two of metal corrosion inhibition, scale inhibition, suspended matter dispersion, biocide efficacy, or biofilm removal/biofilm dispersion is taught by the use of at least one compound which is a salt derived from a thioamine or an oxyamine and an acid.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: March 20, 2018
    Assignee: AMSA, Inc.
    Inventors: Attila G Relenyi, Anthony P Haag
  • Patent number: 9427420
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: August 30, 2016
    Assignee: Synchroneuron, Inc.
    Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
  • Patent number: 9283198
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: March 15, 2016
    Assignee: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: Hao Yi Liang, Francis Chi, Qingfu Xu, Bill Piu Chan
  • Patent number: 9210936
    Abstract: Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and 2-(decylthio)ethanamine compound. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: December 15, 2015
    Assignee: Dow Global Technologies LLC
    Inventors: Bei Yin, Sheila M. Tinetti
  • Publication number: 20150125526
    Abstract: The present disclosure is directed to methods for treating inherited or acquired mitochondrial disease using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Patrice Rioux, Todd C. Zankel
  • Publication number: 20150099806
    Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b??I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Application
    Filed: December 14, 2014
    Publication date: April 9, 2015
    Inventors: Michael D. WARD, Zina ZHU
  • Publication number: 20150094373
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
  • Publication number: 20150080476
    Abstract: The present invention is directed to a method for treating skin inflammatory diseases such as dermatitis, psoriasis, and acne, and rosacea, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The method alleviates the symptoms of the disease treated. The active compound can be administered by a systemic route or topical route. Topical administration is a preferred route of administration.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventor: Joseph P. ST. LAURENT
  • Publication number: 20150056305
    Abstract: Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 26, 2015
    Applicant: PARION SCIENCES, INC.
    Inventors: Michael R. Johnson, William R. Thelin, Ronald A. Aungst, JR.
  • Publication number: 20150030579
    Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 29, 2015
    Applicant: DSM IP ASSETS B.V.
    Inventors: Ann FOWLER, Angelika FRIEDEL, Darko KNUTTI, Karin KURATLI, Daniel RAEDERSTORFF, Ying WANG-SCHMIDT, Karin WERTZ
  • Patent number: 8937050
    Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: January 20, 2015
    Assignees: The Johns Hopkins University, Kennedy Krieger Institute, Inc.
    Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith
  • Patent number: 8933119
    Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: January 13, 2015
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Publication number: 20150011611
    Abstract: In some aspects, methods of inhibiting survival or proliferation of a tumor cell are provided, the methods comprising inhibiting the glycine cleavage system (GCS) of the tumor cell. In some aspects, methods of treating a subject in need of treatment for a tumor, the method comprising inhibiting the GCS in the tumor. In some embodiments, the methods comprise contacting a tumor cell or tumor with a GCS inhibitor. In some embodiments, the tumor cell or tumor has elevated expression of serine hydroxymethyltransferase 2 (SH1VIT2). In some aspects, methods of identifying a tumor cell or tumor that is sensitive to inhibiting the GCS are provided, the methods comprising determining whether the tumor cell or tumor overexpresses SHMT2. In some aspects, methods of identifying a candidate anti-cancer agent are provided, the methods comprising identifying or modifying a GCS inhibitor.
    Type: Application
    Filed: February 11, 2013
    Publication date: January 8, 2015
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Dohoon Kim, David M. Sabatini, Richard Possemato
  • Publication number: 20140370085
    Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
    Type: Application
    Filed: June 17, 2014
    Publication date: December 18, 2014
    Inventors: Kathlene Powell, Ramesh Muttavarapu
  • Patent number: 8883855
    Abstract: Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: November 11, 2014
    Assignee: North Texas Medical Associates
    Inventor: Ivan E. Danhof
  • Publication number: 20140322315
    Abstract: Provided herein are methods and compositions for treating ischemia or a disease or disorder that causes ischemia comprising contacting a subject with cysteamine, a cysteamine derivative, cystamine or a cystamine derivative. The disclosure also provides methods of modulating adiponectin levels in a subject comprising contact a subject with cysteamine, a cysteamine derivative, cystamine or a cystamine derivative.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 30, 2014
    Applicant: The Regents of the University of California
    Inventors: Ranjan Dohil, Susan A. Phillips
  • Publication number: 20140314841
    Abstract: The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 23, 2014
    Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv
    Inventors: Raj K. Puri, Bharat H. Joshi, Benjamin Rubin
  • Patent number: 8865769
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 21, 2014
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Patent number: 8859464
    Abstract: Embodiments of the present invention disclose an agricultural composition that is a field ready spray or a tank mix that includes at least one nitrogen containing isethionic acid salt, at least one agriculturally active ingredient, and at least one surfactant.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: October 14, 2014
    Assignee: Huntsman Petrochemical L LC
    Inventors: R. Scott Tann, Howard M. Stridde
  • Publication number: 20140288117
    Abstract: The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventor: Bill Piu CHAN
  • Publication number: 20140275279
    Abstract: Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.
    Type: Application
    Filed: October 26, 2011
    Publication date: September 18, 2014
    Applicant: SEATTLE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Allison A. Eddy, Daryl M. Okamura
  • Patent number: 8815942
    Abstract: The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., Plasmodium parasites) and/or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and/or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and/or salts thereof.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: August 26, 2014
    Assignee: The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Philippe Gros, Gundula Min-Oo, Anny Fortin
  • Publication number: 20140228296
    Abstract: The present invention relates to the discovery that an increased fraction of albumin is carbamylated in patients suffering from kidney disease (e.g., end-stage renal disease) and that the fraction of carbamylated albumin is also correlated with increased disease severity, particularly risk of mortality. The present invention also relates to the discovery that free amino acids can reduce carbamylation of albumin. Based on these discoveries the present invention provides diagnostic and prognostic methods for patients suffering from, or suspected of suffering from kidney disease. The invention also provides methods for treating kidney disease by administration of a compound or composition that reduced protein carbamylation, such as free amino acids or dipeptides.
    Type: Application
    Filed: July 13, 2012
    Publication date: August 14, 2014
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anders H. Berg, S. Ananth Karumanchi, Ravi I. Thadhani
  • Publication number: 20140140932
    Abstract: The present disclosure provides functionalized magnetic nanoparticles (MNPs) comprising a functional group that binds to ?-amyloid deposits and/or neurofibrillary tangles. The present disclosure provides compositions comprising the functionalized MNPs, and methods of using the functionalized MNPs in imaging ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: April 4, 2012
    Publication date: May 22, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Masoud Akhtari
  • Publication number: 20140107217
    Abstract: The synthesis, growth inhibition and radioprotective activity of the PrC-210 aminothiol, 3-(methyl-amino)-2-((methylamino)methyl)propane-1-thiol, and its polyamine and thiolated polyamine progenitors are reported. All of the molecules significantly inhibited growth of cultured normal human fibroblasts. The combination of an ROS-scavenging thiol group and a positively charged alkyl-amine backbone provided the most radioprotective aminothiol molecule.
    Type: Application
    Filed: August 1, 2013
    Publication date: April 17, 2014
    Inventor: William E. Fahl
  • Publication number: 20140107216
    Abstract: The synthesis, growth inhibition and radioprotective activity of the PrC-210 aminothiol, 3-(methyl-amino)-2-((methylamino)methyl)propane-1-thiol, and its polyamine and thiolated polyamine progenitors are reported. All of the molecules significantly inhibited growth of cultured normal human fibroblasts. The combination of an ROS-scavenging thiol group and a positively charged alkyl-amine backbone provided the most radioprotective aminothiol molecule.
    Type: Application
    Filed: August 1, 2013
    Publication date: April 17, 2014
    Inventor: William E. Fahl
  • Publication number: 20140073611
    Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 13, 2014
    Applicant: National Taiwan University
    Inventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
  • Publication number: 20140073694
    Abstract: The present invention relates to the use of cystamine analogues for the treatment of Parkinson's disease. The present invention also relates to the use of composition comprising cystamine analogues and cysteine. The present invention relates to a method for modifying the progression of Parkinson's disease comprising administering a therapeutically effective amount of at least one cystamine analogue or a pharmaceutically acceptable salt of a cystamine analogue to a patient in need thereof.
    Type: Application
    Filed: February 23, 2012
    Publication date: March 13, 2014
    Applicant: UNIVERSITE LAVAL
    Inventors: Francesca Cicchetti, Claude Rouillard, Frederic Calon
  • Publication number: 20140057877
    Abstract: This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.
    Type: Application
    Filed: October 18, 2011
    Publication date: February 27, 2014
    Inventors: Michael A. Murphy, Mitchell R. Malachowski
  • Publication number: 20140011887
    Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
    Type: Application
    Filed: September 9, 2013
    Publication date: January 9, 2014
    Applicant: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: WEN QIN TANG, FRANCIS CHI
  • Patent number: 8618178
    Abstract: The invention relates to methods for treating T cell mediated autoimmune diseases, such as psoriasis and multiple sclerosis, in a human in need thereof, wherein a therapeutically effective amount of a substance which lowers the cellular glutathione content is administered to the human.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: December 31, 2013
    Assignee: Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
    Inventors: Martin Roecken, Kamran Ghoreschi, Christina Mathilde Weigert
  • Publication number: 20130338225
    Abstract: A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Application
    Filed: May 24, 2013
    Publication date: December 19, 2013
    Applicant: NEW YORK UNIVERSITY
    Inventors: Michael D. Ward, Jeffrey Rimer
  • Publication number: 20130338113
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Application
    Filed: April 4, 2013
    Publication date: December 19, 2013
    Applicant: OBIO PHARMACEUTICAL (H.K.) LIMITED
    Inventors: HAO YI LIANG, FRANCIS CHI, QINGFU XU, BILL PIU CHAN
  • Publication number: 20130337046
    Abstract: The disclosure relates to methods of improving safety, efficacy, or both, of pharmaceutically active aminothiol compounds by delivering them in a thiol-protected form and, preferably intracellularly.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 19, 2013
    Inventors: Dale M. WALKER, Vernon E. WALKER
  • Publication number: 20130316961
    Abstract: The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome.
    Type: Application
    Filed: October 24, 2011
    Publication date: November 28, 2013
    Applicants: UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Jean-Christophe Roux, Laurent Villard, Frédéric Saudou
  • Publication number: 20130310329
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Application
    Filed: May 16, 2013
    Publication date: November 21, 2013
    Applicant: I.E.R.F.C. EUROPEAN INSTITUTE FOR CYSTIC FIBROSIS RESEARCH
    Inventor: I.E.R.F.C. European Institute For Cystic Fibrosis Research
  • Publication number: 20130251634
    Abstract: Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and in cells affected by computed tomography (CT) radiation. Subjects receiving ionizing radiation may be those persons suspected of having cancer, or cancer patients having received or currently receiving cancer therapy, and or those patients having received previous ionizing radiation, including those who are approaching or have exceeded the recommended total radiation dose for a person.
    Type: Application
    Filed: September 16, 2011
    Publication date: September 26, 2013
    Applicant: The University of Chicago
    Inventor: David J. Grdina
  • Patent number: 8530523
    Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: September 10, 2013
    Assignee: Omega Bio-Pharma (I.P.1) Ltd.
    Inventors: Wen Qin Tang, Francis Chi
  • Publication number: 20130183351
    Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: September 10, 2012
    Publication date: July 18, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 8450295
    Abstract: The present invention provides an ophthalmic composition containing xanthan gum, or xanthan gum and an amino acid, which has a superior corneal epithelial disorder-treating effect and a superior corneal epithelial cell-protecting effect.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: May 28, 2013
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Koji Doi, Hiroshi Aki
  • Publication number: 20130123203
    Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.
    Type: Application
    Filed: October 31, 2012
    Publication date: May 16, 2013
    Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith
  • Patent number: 8415398
    Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: April 9, 2013
    Assignee: Obio Pharmaceutical (H.K.) Limited
    Inventors: Hao Yi Liang, Francis Chi, Qingfu Xu, Bill Piu Chan
  • Patent number: 8410170
    Abstract: A method for preventing and treating prostatic diseases and skin cancer using naturally or artificially synthesized isothiocyanates compounds or the derivatives or metabolites thereof.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: April 2, 2013
    Assignee: Wuxi JC Pharmaceutical Technology Co., Ltd.
    Inventors: Jingcai Cheng, Jenwei Chiao, Haiya Jin, Chengjuan Zhong
  • Patent number: 8372889
    Abstract: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: February 12, 2013
    Assignee: Omega Biopharma (I.P.3) Limited
    Inventors: Bill Piu Chan, Gary Kwan Po Wong, Jinxian Xu, Francis Chi
  • Publication number: 20130005693
    Abstract: The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid ? peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, ?-synclein, prion protein, tau and superoxide dismutase 1 (SOD1).
    Type: Application
    Filed: September 10, 2012
    Publication date: January 3, 2013
    Applicant: ACCERA, INC.
    Inventor: Samuel T. Henderson
  • Publication number: 20120322885
    Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
    Type: Application
    Filed: August 28, 2012
    Publication date: December 20, 2012
    Inventors: Wen Qin TANG, Francis Chi